# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-05T03:43:22.707691
**Route:** Direct Google API + PDF
**Paper Hash:** c68dc324386c01dd
**Tokens:** 18838 in / 786 out
**Response SHA256:** f9398a5da9e60624

---

I have reviewed the draft paper "Pills and Diplomas: Do Prescription Drug Monitoring Mandates Affect Higher Education Outcomes?" for fatal errors.

**FATAL ERROR 1: Data-Design Alignment**
- **Location:** Section 3.3, page 8 and Section 5.3, page 17.
- **Error:** The paper uses an event study (Figure 3) to test the association between PDMP mandates and overdose mortality using CDC WONDER data covering **1999–2015**. However, Table 4 (page 31) shows that a significant portion of the treatment variation occurs after this window (e.g., 14 jurisdictions adopted mandates between 2016 and 2021). The paper claims to use these mandates as the "identifying variation," but the data used for the mortality analysis excludes the post-treatment period for nearly 40% of the treated jurisdictions.
- **Fix:** Either extend the CDC WONDER mortality data to cover the full treatment period (through 2021/2023) or explicitly state that the mortality analysis is restricted to a sub-sample of early adopters and acknowledge that the identification strategy cannot be validated for late-adopters.

**FATAL ERROR 2: Completeness**
- **Location:** Table 3, page 18.
- **Error:** The sample sizes (N) reported for the drug-type decomposition are logically impossible for a state-level panel covering 50 states and DC over the 2015–2025 period. For example, "Prescription opioids" lists $N=383$. A full panel of 51 jurisdictions over 11 years (2015-2025) should have 561 observations. Even with some missingness, the "Total drug overdose deaths" reports $N=510$, while sub-categories like "Heroin" report $N=340$. The missing 170 observations for heroin are not explained (e.g., suppression due to small cell sizes).
- **Fix:** Provide a clear explanation in the notes for Table 3 regarding why the sample size varies significantly across drug categories (e.g., CDC data suppression for counts $<10$) and ensure the "Total" category matches the expected panel dimensions or explain the attrition.

**FATAL ERROR 3: Internal Consistency**
- **Location:** Abstract (page 1) vs. Section 5.1 (page 13).
- **Error:** The Abstract reports a significant positive effect on enrollment with $ATT = 0.099, SE = 0.048, p = 0.04$. However, Section 5.1 on page 13 states: "For log enrollment, the CS-DiD estimate is 0.099 (SE = 0.048, p = 0.04)... statistically significant at the 5% level at the 5% level." The repetition is a minor prose issue, but more importantly, the results in Table 2 (page 14) list the same coefficient but the text in 5.1 later says "The larger CS-DiD estimate could reflect...". On page 3, the text says the enrollment result "attenuates substantially in the TWFE specification (0.018, SE = 0.012, p = 0.15)". 
- **Fix:** Ensure the p-values and significance descriptions are consistent. Specifically, ensure the discussion of "sensitivity" in the text matches the statistical evidence provided in the table.

**ADVISOR VERDICT: FAIL**